EP0687179A1 - Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders - Google Patents
Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disordersInfo
- Publication number
- EP0687179A1 EP0687179A1 EP94908375A EP94908375A EP0687179A1 EP 0687179 A1 EP0687179 A1 EP 0687179A1 EP 94908375 A EP94908375 A EP 94908375A EP 94908375 A EP94908375 A EP 94908375A EP 0687179 A1 EP0687179 A1 EP 0687179A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxcarbazepine
- carbamazepine
- treatment
- pharmaceutically acceptable
- aids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- anti-convulsants such as carbamazepine and oxcarbazepine, in the treatment of neuro-AIDS.
- the present invention relates to a new therapeutic application of the anticonvulsants chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds.
- Carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds are described as anticonvulsants and antiepileptics in particular in patent EP 50589.
- neuro-AIDS includes dementia, cognitive impairment, neuropathy, myopathy, eye disorders and all neurological symptoms associated with the HIV-1 virus.
- Cortical cell cultures are prepared according to the method described by SINDOU et al., Brain Res., 572, 242-246 (1992). After 8 to 10 days of culture, the neurons having acquired a correct neuritic form are used for the tests. The cells are kept at 37 ° C. in a CO2 oven for the entire experiment.
- Neuronal survival is assessed before and after 24 hours of application of the product to be tested by a colorimetric technique using Tuspan Blue, counting predetermined fields (semi-quantitative method). A minimum of 4 dishes of cultures per concentration (100 neurons per dish) was analyzed.
- GP120 was applied to the culture medium for 24 hours alone at a concentration of 20 pmol and causes neuronal death of the order of 43%.
- the product to be tested in solution in dimethyl sulfoxide (10 " 3M) is applied 5 minutes before the application of GP120 and then incubated for 24 hours at concentrations of 10" 7 to 10 " 8 mol. Neuronal survival is greater than 80%.
- salts with mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenolphthalinate, methylene-bis- ⁇ -oxynaphthoate or substitution derivatives of these derivatives.
- mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenolphthalinate, methylene-bis- ⁇ -oxynaphthoate or substitution derivatives of these derivatives.
- the medicaments consist of at least one anticonvulsant chosen from carbamazepine and oxcarbazepine in free form or in the form of an addition salt with a pharmaceutically acceptable acid, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active.
- the medicaments according to the invention can be used orally or parenterally.
- compositions for oral administration tablets, pills, powders (gelatin capsules, cachets) or granules can be used.
- the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon.
- inert diluents such as starch, cellulose, sucrose, lactose or silica
- These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
- compositions for oral administration solutions, suspensions, emulsions, syrups and pharmaceutically acceptable elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil.
- inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil.
- These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
- the sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions.
- solvent or vehicle water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable.
- These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- the doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 50 and 400 mg per day orally for an adult with unit doses ranging from 25 to 200 mg of active substance.
- the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
- Tablets containing 50 mg of active product having the following composition are prepared according to the usual technique:
- capsules containing 50 mg of active product having the following composition are prepared:
- a solution for injection containing 10 mg of active product having the following composition is prepared:
- the invention also relates to the process for the preparation of medicaments useful in the treatment of neuro-AIDS consisting in mixing an anticonvulsant chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds with one or more compatible diluents and / or adjuvants and pharmaceutically acceptable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to the application of riluzole or the pharmaceutically acceptable salts of this compound in the treatment of neuro-AIDS.
Description
Application d'anticonvulsivants comme la carbamazepine et l 'oxcarbazépine, dans le traitement du neuro-SIDA. Application of anti-convulsants such as carbamazepine and oxcarbazepine, in the treatment of neuro-AIDS.
La présente invention concerne une nouvelle application thérapeutique des anticonvulsivants choisis parmi la carbamazepine et l'oxcarbazépine ou les sels pharmaceutiquement acceptables de ces composés.The present invention relates to a new therapeutic application of the anticonvulsants chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds.
La carbamazepine et l'oxcarbazépine ou les sels pharmaceutiquement acceptables de ces composés sont décrits comme anticonvulsivants et antiépileptiques notamment dans le brevet EP 50589.Carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds are described as anticonvulsants and antiepileptics in particular in patent EP 50589.
II a maintenant été trouvé de manière surprenante que ces composés peuvent aussi être utilisés dans le traitement du neuro-SIDA.It has now surprisingly been found that these compounds can also be used in the treatment of neuro-AIDS.
Le terme neuro-SIDA comprend les troubles démentiels, les troubles cognitifs, les neuropathies, les myopathies, les troubles occulaires et tous les symptômes neurologiques liés au virus HIV-1.The term neuro-AIDS includes dementia, cognitive impairment, neuropathy, myopathy, eye disorders and all neurological symptoms associated with the HIV-1 virus.
L'activité des composés dans le neuro-SIDA a été mise en évidence dans le test de la mort neuronale induite par la protéine GP-120, protéine d'enveloppe du virus HIV-1 selon le protocole suivant :The activity of the compounds in neuro-AIDS has been demonstrated in the test of neuronal death induced by the GP-120 protein, envelope protein of the HIV-1 virus according to the following protocol:
Des cultures de cellules corticales sont préparées selon la méthode décrite par SINDOU et coll., Brain Res., 572, 242-246 (1992). Après 8 à 10 jours de culture, les neurones ayant acquis une forme neuritique correcte sont utilisés pour les tests. Les cellules sont gardées à 37°C dans une étuve à CO2 pour l'ensemble de l'expérience.Cortical cell cultures are prepared according to the method described by SINDOU et al., Brain Res., 572, 242-246 (1992). After 8 to 10 days of culture, the neurons having acquired a correct neuritic form are used for the tests. The cells are kept at 37 ° C. in a CO2 oven for the entire experiment.
La survie neuronale est appréciée avant et après 24 heures d'application du produit à tester par une technique colorimétrique au Bleu de Tuspan en comptant des champs prédéterminés (méthode semi- quantitative). Un minimum de 4 boîtes de cultures par concentration (100 neurones par boites) a été analysé.Neuronal survival is assessed before and after 24 hours of application of the product to be tested by a colorimetric technique using Tuspan Blue, counting predetermined fields (semi-quantitative method). A minimum of 4 dishes of cultures per concentration (100 neurons per dish) was analyzed.
Dans une première série, la survie neuronale du milieu de culture a été déterminée sans aucun produit. La survie neuronale est alors d'environ 87%.
Dans une deuxième série, la toxicité de la GP120 en culture a été mise en évidence. La GP120 a été appliquée sur le milieu de culture pendant 24 heures seule à une concentration de 20 pmol et entraîne une mort neuronale de l'ordre de 43%.In a first series, the neuronal survival of the culture medium was determined without any product. Neuronal survival is then around 87%. In a second series, the toxicity of GP120 in culture was highlighted. GP120 was applied to the culture medium for 24 hours alone at a concentration of 20 pmol and causes neuronal death of the order of 43%.
Dans la troisième série, le produit à tester en solution dans le diméthylsulfoxyde (10"3 M) est appliqué 5 minutes avant l'application de GP120 et incubé ensuite pendant 24 heures à des concentrations de 10"7 à 10"8 mol.. La survie neuronale est supérieure à 80%.In the third series, the product to be tested in solution in dimethyl sulfoxide (10 " 3M) is applied 5 minutes before the application of GP120 and then incubated for 24 hours at concentrations of 10" 7 to 10 " 8 mol. Neuronal survival is greater than 80%.
Comme sels pharmaceutiquement acceptables peuvent être notamment cités les sels d'addition avec les acides minéraux tels que chlorhydrate, sulfate, nitrate, phosphate ou organiques tels que acétate, propionate, succinate, oxalate, benzoate, fumarate, maléate, méthanesulfonate, iséthionate, théophilline-acétate, salicylate, phénolphtalinate, méthylène-bis-β-oxynaphtoate ou des dérivés de substitution de ces dérivés.As pharmaceutically acceptable salts, mention may in particular be made of addition salts with mineral acids such as hydrochloride, sulfate, nitrate, phosphate or organic salts such as acetate, propionate, succinate, oxalate, benzoate, fumarate, maleate, methanesulfonate, isethionate, theophillin- acetate, salicylate, phenolphthalinate, methylene-bis-β-oxynaphthoate or substitution derivatives of these derivatives.
Les médicaments sont constitués par au moins un anticonvulsivant choisi parmi la carbamazepine et l'oxcarbazépine sous forme libre ou sous forme d'un sel d'addition avec un acide pharmaceutiquement acceptable, à l'état pur ou sous forme d'une composition dans laquelle il est associé à tout autre produit pharmaceutiquement compatible, pouvant être inerte ou physiologiquement actif. Les médicaments selon l'invention peuvent être employés par voie orale ou parentérale.The medicaments consist of at least one anticonvulsant chosen from carbamazepine and oxcarbazepine in free form or in the form of an addition salt with a pharmaceutically acceptable acid, in the pure state or in the form of a composition in which it is associated with any other pharmaceutically compatible product, which may be inert or physiologically active. The medicaments according to the invention can be used orally or parenterally.
Comme compositions solides pour administration orale, peuvent être utilisés des comprimés, des pilules, des poudres (capsules de gélatine, cachets) ou des granulés. Dans ces compositions, le principe actif selon l'invention est mélangé à un ou plusieurs diluants inertes, tels que amidon, cellulose, saccharose, lactose ou silice, sous courant d'argon. Ces compositions peuvent également comprendre des substances autres que les diluants, par exemple un ou plusieurs lubrifiants tels que le stéarate de magnésium ou le talc, un colorant, un enrobage (dragées) ou un vernis.As solid compositions for oral administration, tablets, pills, powders (gelatin capsules, cachets) or granules can be used. In these compositions, the active principle according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under a stream of argon. These compositions can also comprise substances other than diluents, for example one or more lubricants such as magnesium stearate or talc, a dye, a coating (dragees) or a varnish.
Comme compositions liquides pour administration orale, on peut utiliser des solutions, des suspensions, des émulsions, des sirops et des
élixirs pharmaceutiquement acceptables contenant des diluants inertes tels que l'eau, l'éthanol, le glycérol, les huiles végétales ou l'huile de paraffine. Ces compositions peuvent comprendre des substances autres que les diluants, par exemple des produits mouillants, édulcorants, épaississants, aromatisants ou stabilisants.As liquid compositions for oral administration, solutions, suspensions, emulsions, syrups and pharmaceutically acceptable elixirs containing inert diluents such as water, ethanol, glycerol, vegetable oils or paraffin oil. These compositions can include substances other than diluents, for example wetting, sweetening, thickening, flavoring or stabilizing products.
Les compositions stériles pour administration parentérale, peuvent être de préférence des solutions aqueuses ou non aqueuses, des suspensions ou des émulsions. Comme solvant ou véhicule, on peut employer l'eau, le propylèneglycol, un polyéthylèneglycol, des huiles végétales, en particulier l'huile d'olive, des esters organiques injectables, par exemple l'oléate d'éthyle ou d'autres solvants organiques convenables. Ces compositions peuvent également contenir des adjuvants, en particulier des agents mouillants, isotonisants, émulsifiants, dispersants et stabilisants. La stérilisation peut se faire de plusieurs façons, par exemple par filtration aseptisante, en incorporant à la composition des agents stérilisants, par irra¬ diation ou par chauffage. Elles peuvent également être préparées sous forme de compositions solides stériles qui peuvent être dissoutes au moment de l'emploi dans de l'eau stérile ou tout autre milieu stérile injectable.The sterile compositions for parenteral administration can preferably be aqueous or non-aqueous solutions, suspensions or emulsions. As solvent or vehicle, water, propylene glycol, polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate or other organic solvents can be used. suitable. These compositions can also contain adjuvants, in particular wetting agents, isotonizers, emulsifiers, dispersants and stabilizers. Sterilization can be done in several ways, for example by aseptic filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They can also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
Les doses dépendent de l'effet recherché, de la durée du traitement et de la voie d'administration utilisée ; elles sont généralement comprises entre 50 et 400 mg par jour par voie orale pour un adulte avec des doses unitaires allant de 25 à 200 mg de substance active.The doses depend on the desired effect, on the duration of the treatment and on the route of administration used; they are generally between 50 and 400 mg per day orally for an adult with unit doses ranging from 25 to 200 mg of active substance.
D'une façon générale, le médecin déterminera la posologie appropriée en fonction de l'âge, du poids et de tous les autres facteurs propres au sujet à traiter.In general, the doctor will determine the appropriate dosage based on age, weight and all other factors specific to the subject to be treated.
Les exemples suivants illustrent des médicaments selon l'invention :The following examples illustrate medicaments according to the invention:
Exemple AExample A
On prépare, selon la technique habituelle, des comprimés dosés à 50 mg de produit actif ayant la composition suivante :Tablets containing 50 mg of active product having the following composition are prepared according to the usual technique:
- Produit actif 50 mg- Active product 50 mg
- Mannitol 64 mg
- Cellulose microcristalline 50 mg- Mannitol 64 mg - Microcrystalline cellulose 50 mg
- Polyvidone excipient 12 mg- Polyvidone excipient 12 mg
- Carboxyméthylamidon sodique 16 mg- Carboxymethyl starch sodium 16 mg
- Talc 4 mg - Stéarate de magnésium 2 mg- Talc 4 mg - Magnesium stearate 2 mg
- Silice colloïdale anhydre 2 mg- Anhydrous colloidal silica 2 mg
- Mélange de méthylhydroxypropylcellulose, polyéthylèneglycol 6000, dioxyde de titane (72-3,5-24,5) q.s.p. 1 comprimé pellicule terminé à 245 mg- Mixture of methylhydroxypropylcellulose, polyethylene glycol 6000, titanium dioxide (72-3,5-24,5) q.s.p. 1 film-coated tablet finished at 245 mg
Exemple BExample B
On prépare, selon la technique habituelle, des gélules dosées à 50 mg de produit actif ayant la composition suivante :Using the usual technique, capsules containing 50 mg of active product having the following composition are prepared:
- Produit actif 50 mg- Active product 50 mg
- Cellulose 18 mg - Lactose 55 mg- Cellulose 18 mg - Lactose 55 mg
- Silice colloïdale 1 mg- Colloidal silica 1 mg
- Carboxyméthylamidon sodique 10 mg- Carboxymethyl starch sodium 10 mg
- Talc 10 mg- Talc 10 mg
- Stéarate de magnésium 1 mg- Magnesium stearate 1 mg
Exemple CExample C
On prépare une solution injectable contenant 10 mg de produit actif ayant la composition suivante :A solution for injection containing 10 mg of active product having the following composition is prepared:
- Produit actif 10 mg- Active product 10 mg
- Acide benzoïque 80 mg - Alcool benzylique 0,06 cm3- Benzoic acid 80 mg - Benzyl alcohol 0.06 cm3
- Benzoate de sodium 80 mg- Sodium benzoate 80 mg
- Ethanol à 95 % 0,4 cm3- 95% ethanol 0.4 cm3
- Hydroxyde de sodium 24 mg- Sodium hydroxide 24 mg
- Propylène glycol 1 ,6 cm3 - Eau q.s.p. 4 cm3
L'invention concerne également le procédé de préparation de médicaments utiles dans le traitement du neuro-SIDA consistant à mélanger un anticonvulsivant choisi parmi la carbamazepine et l'oxcarbazépine ou les sels pharmaceutiquement acceptables de ces composés avec un ou plusieurs diluants et/ou adjuvants compatibles et pharmaceutiquement acceptables.
- Propylene glycol 1.6 cm3 - Water qs 4 cm3 The invention also relates to the process for the preparation of medicaments useful in the treatment of neuro-AIDS consisting in mixing an anticonvulsant chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds with one or more compatible diluents and / or adjuvants and pharmaceutically acceptable.
Claims
REVENDICATIONS
1 - Application d'un anticonvulsivant choisi parmi la carbamazepine et l'oxcarbazépine ou les sels pharmaceutiquement acceptables de ces composés à la préparation de médicaments destinés au traitement du neuro- SIDA.1 - Application of an anticonvulsant chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds in the preparation of medicaments intended for the treatment of neuro AIDS.
2 - Application selon la revendication 1 pour la préparation de médicaments destinés au traitement des troubles démentiels, des troubles cognitifs, des neuropathies, de la myopathie, des troubles occulaires et de tous les symptômes neurologiques liés au virus HIV 1.2 - Application according to claim 1 for the preparation of medicaments intended for the treatment of dementia disorders, cognitive disorders, neuropathies, myopathy, ocular disorders and all the neurological symptoms linked to the HIV 1 virus.
3 - Application selon la revendication 1 pour- obtenir un médicament comprenant 25 à 200 mg de l'anticonvulsivant.3 - Application according to claim 1 pour- obtain a medicament comprising 25 to 200 mg of the anti-convulsant.
4 - Procédé de préparation d'un médicament utile pour le traitement du neuro-SIDA caractérisé en ce que l'on mélange un anticonvulsivant choisi parmi la carbamazepine et l'oxcarbazépine ou les sels pharmaceutiquement acceptables de ces composés avec un ou plusieurs diluants et/ou adjuvants compatibles et pharaceutiquement acceptables.
4 - Process for the preparation of a medicament useful for the treatment of neuro-AIDS characterized in that an anticonvulsant chosen from carbamazepine and oxcarbazepine or the pharmaceutically acceptable salts of these compounds is mixed with one or more diluents and / or compatible and pharmacologically acceptable adjuvants.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9302568A FR2702148B1 (en) | 1993-03-05 | 1993-03-05 | Application of anti-convulsants in the treatment of neuro-AIDS. |
FR9302568 | 1993-03-05 | ||
PCT/FR1994/000209 WO1994020110A1 (en) | 1993-03-05 | 1994-02-25 | Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0687179A1 true EP0687179A1 (en) | 1995-12-20 |
Family
ID=9444690
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94908374A Expired - Lifetime EP0687176B1 (en) | 1993-03-05 | 1994-02-25 | Use of riluzole for treating aids-related neural disorders |
EP94908376A Expired - Lifetime EP0687177B1 (en) | 1993-03-05 | 1994-02-25 | Use of lamotrigine for treating aids-related neural disorders |
EP94908375A Withdrawn EP0687179A1 (en) | 1993-03-05 | 1994-02-25 | Use of antiepileptics such as carbamazepine and oxcarbazepine for treating aids-related neural disorders |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94908374A Expired - Lifetime EP0687176B1 (en) | 1993-03-05 | 1994-02-25 | Use of riluzole for treating aids-related neural disorders |
EP94908376A Expired - Lifetime EP0687177B1 (en) | 1993-03-05 | 1994-02-25 | Use of lamotrigine for treating aids-related neural disorders |
Country Status (23)
Country | Link |
---|---|
US (2) | US5629312A (en) |
EP (3) | EP0687176B1 (en) |
JP (3) | JPH08507508A (en) |
KR (3) | KR960700721A (en) |
AT (2) | ATE147981T1 (en) |
AU (3) | AU6143894A (en) |
CA (3) | CA2154571A1 (en) |
CZ (3) | CZ284423B6 (en) |
DE (2) | DE69427344T2 (en) |
DK (2) | DK0687177T3 (en) |
ES (2) | ES2157252T3 (en) |
FR (1) | FR2702148B1 (en) |
GR (2) | GR3022356T3 (en) |
HU (3) | HUT73434A (en) |
IL (3) | IL108845A0 (en) |
NO (3) | NO953372L (en) |
PL (3) | PL310474A1 (en) |
PT (1) | PT687176E (en) |
RU (1) | RU2157205C2 (en) |
SK (3) | SK107595A3 (en) |
UA (1) | UA41355C2 (en) |
WO (3) | WO1994020103A1 (en) |
ZA (2) | ZA941530B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866597A (en) * | 1993-03-19 | 1999-02-02 | Glaxo Wellcome Inc. | Use of triazine compounds for the treatment of memory and learning disorders |
GB9424766D0 (en) * | 1994-12-07 | 1995-02-08 | Wellcome Found | Pharmaceutical composition |
GB9512854D0 (en) * | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
DE19603984A1 (en) * | 1996-02-05 | 1997-08-07 | Bayer Ag | Granules of triazines |
US20020022056A1 (en) | 1997-02-14 | 2002-02-21 | Burkhard Schlutermann | Oxacarbazepine film-coated tablets |
CO4920215A1 (en) * | 1997-02-14 | 2000-05-29 | Novartis Ag | OXACARBAZEPINE TABLETS COATED WITH A FILM AND METHOD FOR THE PRODUCTION OF THESE FORMULATIONS |
US5922746A (en) * | 1997-03-27 | 1999-07-13 | Allergan | Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma |
GB9721497D0 (en) * | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
FR2774592B1 (en) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | APPLICATION OF 2-AMINO-6-TRIFLUOROMETHOXYBENZOTHIAZOLE FOR THE PREVENTION OR TREATMENT OF BRAIN MALFUNCTIONS |
FR2774908B1 (en) * | 1998-02-17 | 2000-06-23 | Centre Nat Rech Scient | USE OF A GLUTAMATE RELEASE INHIBITOR IN THE TREATMENT OF RETINAL ISCHEMIA |
FR2787028B1 (en) * | 1998-12-15 | 2002-10-18 | Aventis Pharma Sa | USE OF RILUZOLE IN THE TREATMENT OF ACOUSTIC TRAUMA |
AU4424500A (en) * | 1999-04-29 | 2000-11-17 | Centre National De La Recherche Scientifique (C.N.R.S.) | A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping |
US7479498B2 (en) | 1999-08-23 | 2009-01-20 | Phoenix Biosciences, Inc. | Treatments for viral infections |
GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
FR2801217B1 (en) * | 1999-11-24 | 2002-12-06 | Aventis Pharma Sa | COMBINATION OF RILUZOLE AND GABAPENTINE AND ITS USE AS A MEDICINAL PRODUCT |
GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
US6207179B1 (en) * | 2000-05-18 | 2001-03-27 | Phoenix Scientific, Inc. | Parasiticidal formulation for animals and a method of making this formulation |
CA2471666C (en) | 2004-06-18 | 2009-10-13 | Apotex Pharmachem Inc. | An improved process for the preparation of oxcarbazepine and related intermediates |
EP1874353A1 (en) * | 2005-04-05 | 2008-01-09 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
FR2910811B1 (en) * | 2007-01-03 | 2009-07-10 | Ass Pour Le Dev De La Biothera | USE OF RILUZOLE AND ITS DERIVATIVES FOR MANUFACTURING NEW DRUGS |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
FR2957077B1 (en) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | USE OF RILUZOLE FOR TREATING OR PREVENTING ADVERSE EFFECTS OF ANTI-CANCER AGENTS |
KR102580378B1 (en) * | 2014-11-21 | 2023-09-19 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Sublingual formulation of riluzole |
CA3209488A1 (en) * | 2021-02-24 | 2022-09-01 | Jacob BONTA | Foaming evaporator coil cleaner |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2492258A1 (en) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | NEW AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE-BASED MEDICINAL PRODUCT |
US4431641A (en) * | 1980-10-17 | 1984-02-14 | Ciba-Geigy Corporation | Pharmaceutical compositions having antiepileptic and antineuralgic action |
GB8613183D0 (en) * | 1986-05-30 | 1986-07-02 | Wellcome Found | Triazine salt |
US4826860A (en) * | 1987-03-16 | 1989-05-02 | Warner-Lambert Company | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents |
US4918090A (en) * | 1988-01-25 | 1990-04-17 | Warner-Lambert Company | Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents |
EP0435826A1 (en) * | 1989-12-27 | 1991-07-03 | Ciba-Geigy Ag | Intravenous solutions for epilepsy |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
FR2688138B1 (en) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS. |
JPH07308499A (en) * | 1994-05-20 | 1995-11-28 | Brother Ind Ltd | Clothes dryer |
-
1993
- 1993-03-05 FR FR9302568A patent/FR2702148B1/en not_active Expired - Lifetime
-
1994
- 1994-02-25 PL PL94310474A patent/PL310474A1/en unknown
- 1994-02-25 CA CA002154571A patent/CA2154571A1/en not_active Abandoned
- 1994-02-25 PL PL94310475A patent/PL310475A1/en unknown
- 1994-02-25 SK SK1075-95A patent/SK107595A3/en unknown
- 1994-02-25 CZ CZ952261A patent/CZ284423B6/en unknown
- 1994-02-25 JP JP6519648A patent/JPH08507508A/en active Pending
- 1994-02-25 JP JP6519649A patent/JPH08507509A/en active Pending
- 1994-02-25 PL PL94310476A patent/PL310476A1/en unknown
- 1994-02-25 EP EP94908374A patent/EP0687176B1/en not_active Expired - Lifetime
- 1994-02-25 SK SK1076-95A patent/SK279659B6/en not_active IP Right Cessation
- 1994-02-25 PT PT94908374T patent/PT687176E/en unknown
- 1994-02-25 AT AT94908376T patent/ATE147981T1/en active
- 1994-02-25 EP EP94908376A patent/EP0687177B1/en not_active Expired - Lifetime
- 1994-02-25 HU HU9502583A patent/HUT73434A/en unknown
- 1994-02-25 AU AU61438/94A patent/AU6143894A/en not_active Abandoned
- 1994-02-25 SK SK1074-95A patent/SK107495A3/en unknown
- 1994-02-25 HU HU9502584A patent/HU9502584D0/en unknown
- 1994-02-25 WO PCT/FR1994/000208 patent/WO1994020103A1/en active IP Right Grant
- 1994-02-25 DE DE69427344T patent/DE69427344T2/en not_active Expired - Lifetime
- 1994-02-25 DK DK94908376.0T patent/DK0687177T3/en active
- 1994-02-25 AU AU61439/94A patent/AU675119B2/en not_active Ceased
- 1994-02-25 HU HU9502585A patent/HU217132B/en not_active IP Right Cessation
- 1994-02-25 CZ CZ952259A patent/CZ285339B6/en not_active IP Right Cessation
- 1994-02-25 CA CA002154573A patent/CA2154573A1/en not_active Abandoned
- 1994-02-25 EP EP94908375A patent/EP0687179A1/en not_active Withdrawn
- 1994-02-25 DK DK94908374T patent/DK0687176T3/en active
- 1994-02-25 WO PCT/FR1994/000209 patent/WO1994020110A1/en not_active Application Discontinuation
- 1994-02-25 ES ES94908374T patent/ES2157252T3/en not_active Expired - Lifetime
- 1994-02-25 AU AU61437/94A patent/AU675118B2/en not_active Ceased
- 1994-02-25 UA UA95083996A patent/UA41355C2/en unknown
- 1994-02-25 ES ES94908376T patent/ES2096455T3/en not_active Expired - Lifetime
- 1994-02-25 CA CA002154572A patent/CA2154572C/en not_active Expired - Fee Related
- 1994-02-25 JP JP51964794A patent/JP3578174B2/en not_active Expired - Fee Related
- 1994-02-25 CZ CZ952260A patent/CZ226095A3/en unknown
- 1994-02-25 DE DE69401577T patent/DE69401577T2/en not_active Expired - Fee Related
- 1994-02-25 AT AT94908374T patent/ATE201597T1/en active
- 1994-02-25 US US08/530,253 patent/US5629312A/en not_active Expired - Fee Related
- 1994-02-25 KR KR1019950703734A patent/KR960700721A/en not_active Application Discontinuation
- 1994-02-25 KR KR1019950703733A patent/KR960700723A/en not_active Application Discontinuation
- 1994-02-25 KR KR1019950703732A patent/KR100318168B1/en not_active IP Right Cessation
- 1994-02-25 RU RU95121731/14A patent/RU2157205C2/en not_active IP Right Cessation
- 1994-02-25 WO PCT/FR1994/000210 patent/WO1994020108A1/en active IP Right Grant
- 1994-03-03 IL IL10884594A patent/IL108845A0/en unknown
- 1994-03-03 IL IL10884694A patent/IL108846A0/en not_active IP Right Cessation
- 1994-03-03 IL IL108844A patent/IL108844A/en not_active IP Right Cessation
- 1994-03-04 ZA ZA941530A patent/ZA941530B/en unknown
- 1994-03-04 ZA ZA941525A patent/ZA941525B/en unknown
-
1995
- 1995-02-28 US US08/396,106 patent/US5624945A/en not_active Expired - Lifetime
- 1995-08-28 NO NO953372A patent/NO953372L/en unknown
- 1995-08-28 NO NO953370A patent/NO307687B1/en not_active IP Right Cessation
- 1995-08-28 NO NO953371A patent/NO953371L/en unknown
-
1997
- 1997-01-23 GR GR960402768T patent/GR3022356T3/en unknown
-
2001
- 2001-05-31 GR GR20010400060T patent/GR3035957T3/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9420110A1 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0687177B1 (en) | Use of lamotrigine for treating aids-related neural disorders | |
EP0678026B1 (en) | Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes | |
WO1993017683A1 (en) | Application of 2-amino 6-trifluoromethoxy benzothiazole (riluzole) for obtaining a drug useful in the treatment of motor neuron diseases | |
EP0738147B1 (en) | Application of riluzole in the treatment of mitochondrial diseases | |
FR2702149A1 (en) | Application of lamotrigine in the treatment of neuro-AIDS | |
FR2619712A1 (en) | APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF SCHIZOPHRENIA | |
FR2702151A1 (en) | Application of anticonvulsants in the treatment of neuro-AIDS | |
FR2619713A1 (en) | APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN MEDICINE FOR THE TREATMENT OF SLEEP AND DEPRESSION DISORDERS | |
WO2001012265A1 (en) | Use of cyamemazine for cold turkey benzodiazepine treatment | |
CA2319686C (en) | Use of 2-amino-6-trifluoromehthoxybenzothiazole for preventing or treating cerebellum dysfunction | |
CA2152280C (en) | Use of riluzole as a radiorestorer | |
FR2700115A1 (en) | Use of anticonvulsants carbamazepine and oxcarbazepine | |
FR2700114A1 (en) | Use of the anticonvulsant lamotrigin and its salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950810 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19970902 |